241 related articles for article (PubMed ID: 26956429)
21. Hyperglycemia-induced transcriptional regulation of ROCK1 and TGM2 expression is involved in small artery remodeling in obese diabetic Göttingen Minipigs.
Ludvigsen TP; Olsen LH; Pedersen HD; Christoffersen BØ; Jensen LJ
Clin Sci (Lond); 2019 Dec; 133(24):2499-2516. PubMed ID: 31830262
[TBL] [Abstract][Full Text] [Related]
22. The transglutaminase 2 gene (TGM2), a potential molecular marker for chemotherapeutic drug sensitivity, is epigenetically silenced in breast cancer.
Ai L; Kim WJ; Demircan B; Dyer LM; Bray KJ; Skehan RR; Massoll NA; Brown KD
Carcinogenesis; 2008 Mar; 29(3):510-8. PubMed ID: 18174247
[TBL] [Abstract][Full Text] [Related]
23. A long non-coding RNA inside the type 2 transglutaminase gene tightly correlates with the expression of its transcriptional variants.
Minotti L; Baldassari F; Galasso M; Volinia S; Bergamini CM; Bianchi N
Amino Acids; 2018 Apr; 50(3-4):421-438. PubMed ID: 29313085
[TBL] [Abstract][Full Text] [Related]
24. Tissue transglutaminase inhibits autophagy in pancreatic cancer cells.
Akar U; Ozpolat B; Mehta K; Fok J; Kondo Y; Lopez-Berestein G
Mol Cancer Res; 2007 Mar; 5(3):241-9. PubMed ID: 17374730
[TBL] [Abstract][Full Text] [Related]
25. Humanization of the mouse mammary gland by replacement of the luminal layer with genetically engineered preneoplastic human cells.
Verbeke S; Richard E; Monceau E; Schmidt X; Rousseau B; Velasco V; Bernard D; Bonnefoi H; MacGrogan G; Iggo RD
Breast Cancer Res; 2014 Dec; 16(6):504. PubMed ID: 25527189
[TBL] [Abstract][Full Text] [Related]
26. The TP53 tumor suppressor and autophagy in malignant lymphoma.
Xu-Monette ZY; Young KH
Autophagy; 2012 May; 8(5):842-5. PubMed ID: 22498492
[TBL] [Abstract][Full Text] [Related]
27. Transglutaminase 2 and NF-κB: an odd couple that shapes breast cancer phenotype.
Brown KD
Breast Cancer Res Treat; 2013 Jan; 137(2):329-36. PubMed ID: 23224146
[TBL] [Abstract][Full Text] [Related]
28. Psammaplin A induces Sirtuin 1-dependent autophagic cell death in doxorubicin-resistant MCF-7/adr human breast cancer cells and xenografts.
Kim TH; Kim HS; Kang YJ; Yoon S; Lee J; Choi WS; Jung JH; Kim HS
Biochim Biophys Acta; 2015 Feb; 1850(2):401-10. PubMed ID: 25445714
[TBL] [Abstract][Full Text] [Related]
29. Transglutaminase 2 accelerates vascular calcification in chronic kidney disease.
Chen NX; O'Neill K; Chen X; Kiattisunthorn K; Gattone VH; Moe SM
Am J Nephrol; 2013; 37(3):191-8. PubMed ID: 23466870
[TBL] [Abstract][Full Text] [Related]
30. Oncogenic ras activates the ARF-p53 pathway to suppress epithelial cell transformation.
Lin AW; Lowe SW
Proc Natl Acad Sci U S A; 2001 Apr; 98(9):5025-30. PubMed ID: 11309506
[TBL] [Abstract][Full Text] [Related]
31. G2A is an oncogenic G protein-coupled receptor.
Zohn IE; Klinger M; Karp X; Kirk H; Symons M; Chrzanowska-Wodnicka M; Der CJ; Kay RJ
Oncogene; 2000 Aug; 19(34):3866-77. PubMed ID: 10951580
[TBL] [Abstract][Full Text] [Related]
32. The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells.
Zhao JJ; Liu Z; Wang L; Shin E; Loda MF; Roberts TM
Proc Natl Acad Sci U S A; 2005 Dec; 102(51):18443-8. PubMed ID: 16339315
[TBL] [Abstract][Full Text] [Related]
33. ISGylation governs the oncogenic function of Ki-Ras in breast cancer.
Burks J; Reed RE; Desai SD
Oncogene; 2014 Feb; 33(6):794-803. PubMed ID: 23318454
[TBL] [Abstract][Full Text] [Related]
34. TGM2 and implications for human disease: role of alternative splicing.
Lai TS; Greenberg CS
Front Biosci (Landmark Ed); 2013 Jan; 18(2):504-19. PubMed ID: 23276939
[TBL] [Abstract][Full Text] [Related]
35. A degradative detour for mutant TP53.
Vakifahmetoglu-Norberg H; Yuan J
Autophagy; 2013 Dec; 9(12):2158-60. PubMed ID: 24145670
[TBL] [Abstract][Full Text] [Related]
36. Monocytic Tissue Transglutaminase in a Rat Model for Reversible Acute Rejection and Chronic Renal Allograft Injury.
Zakrzewicz A; Atanasova S; Padberg W; Grau V
Mediators Inflamm; 2015; 2015():429653. PubMed ID: 26063971
[TBL] [Abstract][Full Text] [Related]
37. An ShRNA Based Genetic Screen Identified Sesn2 as a Potential Tumor Suppressor in Lung Cancer via Suppression of Akt-mTOR-p70S6K Signaling.
Xu H; Sun H; Zhang H; Liu J; Fan F; Li Y; Ning X; Sun Y; Dai S; Liu B; Gao M; Fu S; Zhou C
PLoS One; 2015; 10(5):e0124033. PubMed ID: 25962159
[TBL] [Abstract][Full Text] [Related]
38. p53-mediated growth suppression in response to Nutlin-3 in cyclin D1 transformed cells occurs independently of p21.
Kan CE; Patton JT; Stark GR; Jackson MW
Cancer Res; 2007 Oct; 67(20):9862-8. PubMed ID: 17942917
[TBL] [Abstract][Full Text] [Related]
39. Maintaining genetic stability through TP53 mediated checkpoint control.
Wahl GM; Linke SP; Paulson TG; Huang LC
Cancer Surv; 1997; 29():183-219. PubMed ID: 9338102
[TBL] [Abstract][Full Text] [Related]
40. Tissue transglutaminase-2 promotes gastric cancer progression via the ERK1/2 pathway.
Wang X; Yu Z; Zhou Q; Wu X; Chen X; Li J; Zhu Z; Liu B; Su L
Oncotarget; 2016 Feb; 7(6):7066-79. PubMed ID: 26771235
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
